China's RemeGen nets $100m led by Lilly Asia Ventures, Lake Bleu Capital

China's RemeGen nets $100m led by Lilly Asia Ventures, Lake Bleu Capital

RemeGen's buildings for the development of antibody and biological agents. Source: RemeGen

Chinese biopharmaceutical firm RemeGen announced on Tuesday the completion of over $100 million in a new funding round jointly led China-based biomedical venture capital firm Lilly Asia Ventures, and Hong Kong’s healthcare investment fund Lake Bleu Capital.